# MediFab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medifab

- Industry: Medical Devices & Equipment
- Headquarters: Seoul, South Korea
- Website: www.imedifab.com
- Total disclosed funding: $20M
- Latest round: Series B (Oct 24, 2025)
- Investors on record: 12

## About

Based in Seoul, South Korea, and founded in 2016, MediFab develops, produces, and supplies prosthesis that replaces silicon and filler by using biomaterial for tissue repair and 3D printing technologies. In 2016, the company released Cellrix 3D's culture system, signed a contract with Seoul Boramae Hospital on cooperative research, and another contract with Seoul National University on university-industry technical service development. MediFab developed a 3D printing-based self-healing implant and made a casting trap for making 3D cell culture support in 2018. In 2019, the company received a patent from the United States for its method for manufacturing three-dimensional cell culture support's double crosslink and casting tray for manufacturing three-dimensional cell culture support.

The company develops and manufactures Cellrix 3D, a culture system developed with new 3D cell culture technology that forms an implantable 3D culture deposited with cell, creates cell environment closest to in-vivo, and is suitable for researches such as stem cell, spheroid 3D culture, and cancer research.

## Funding rounds

- Series B, Oct 24, 2025, $17M — Mirae Asset Venture Investment, QUAD Investment Management, BNK Securities, Murex Partners, DAYLI Partners, Hanwha Investment & Securities, Sneak Peek Investment, Pathway Partners, Mirae Asset Capital
- Series A, Oct 26, 2021, $3.4M — Shinhan Capital, Soo Investment Capital, PharmaResearch

## Investors

- Shinhan Capital (https://capitalatlas.ai/funds/shinhan-capital) — Series A
- Soo Investment Capital (https://capitalatlas.ai/funds/soo-investment-capital) — Series A
- PharmaResearch — Series A
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series B
- QUAD Investment Management (https://capitalatlas.ai/funds/quad-investment-management) — Series B
- BNK Securities (https://capitalatlas.ai/funds/bnk-securities) — Series B
- Murex Partners (https://capitalatlas.ai/funds/murex-partners) — Series B
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series B
- Hanwha Investment & Securities (https://capitalatlas.ai/funds/hanwha-investment-securities) — Series B
- Sneak Peek Investment (https://capitalatlas.ai/funds/sneak-peek-investment) — Series B
- Pathway Partners (https://capitalatlas.ai/funds/pathway-partners) — Series B
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series B